Form 4: ANI Pharmaceuticals Executive Sells 250 Shares Under 10b5-1 Trading Plan

Meredith Cook, Senior VP, General Counsel & Secretary of ANI Pharmaceuticals, sold 250 shares of common stock at $56.24 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Meredith Cook, a Senior VP, General Counsel & Secretary at ANI Pharmaceuticals, sold 250 shares of the company's common stock.
• The transaction occurred on December 13, 2024, at a price of $56.24 per share.
• This sale was executed under a pre-existing Rule 10b5-1 trading plan adopted on August 11, 2023.
• Following the transaction, Ms. Cook directly owns 55,988 shares of ANI Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of an insider stock sale under a pre-arranged plan, which is neither positive nor negative for the company's outlook.

Industry Context

This is a routine disclosure of an insider stock sale, which is common in publicly traded companies. The use of a 10b5-1 plan indicates the sale was pre-planned and not based on any non-public information.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a standard practice for executives at publicly traded companies to avoid accusations of insider trading.
• Similar filings are regularly made by executives at comparable pharmaceutical companies such as Teva Pharmaceuticals, Mylan, and Perrigo, when they execute pre-planned stock sales.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on shareholder sentiment, but the pre-planned nature of the sale mitigates any significant concern.

Key Dates

Keywords

ANI Pharmaceuticals, insider trading, Form 4, Meredith Cook, stock sale, Rule 10b5-1, executive, share transaction